ArticleCancer chemotherapy and pharmacology2020

YLZ-F5, a novel polo-like kinase 4 inhibitor, inhibits human ovarian cancer cell growth by inducing apoptosis and mitotic defects.

Yongxia Zhu et al.PubMed ↗Publisher ↗

No numbers read from the abstract.